Skip to content

Fecal Microbiota Transplant (FMT) for Relapsing C. Difficile Infection in Adults and Children Using a Frozen Inoculum

Fecal Microbiota Transplant (FMT) for Relapsing C. Difficile Infection in Adults and Children Using a Frozen Inoculum

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01704937
Enrollment
20
Registered
2012-10-12
Start date
2012-11-30
Completion date
2014-05-31
Last updated
2014-06-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Clostridium Difficile Infection

Keywords

Fecal Microbiota Transplant, Clostridium difficile, Diarrhea

Brief summary

Fecal microbiota transplantation (FMT) is the reconstitution of normal flora by a stool transplant from a healthy individual to a C. difficile-infected recipient, and has long been a successful approach to recurrent/refractory C. difficile. The purpose of this project is to generate a frozen FMT inoculum from well-screened healthy volunteer donors which can be used repeatedly, particularly in those who do not have a healthy intimate partner or other related donor. Delivery of FMT has been performed colonoscopically, by fecal retention enema, or by the nasogastric route. This study will evaluate the safety and secondarily the efficacy of a frozen inoculum administered by nasogastric tube vs administered by colonoscope. Subjects with recurrent/relapsing C. difficile infection (10 per group) will receive FMT via either: * colonoscopy * NGT The primary endpoint is assessment of safety as measured by clinical events (GI, procedural, systemic). Efficacy will be defined as a resolution of diarrhea off antibiotics for C. difficile, in the absence of a need for OTHER systemic antibiotics, i.e. resumption of a normal bowel status for the individual. Secondary efficacy endpoints include weight, subjective well-being and relative clinical improvement per standardized questionnaire, and subject qualitative assessment of, and satisfaction with, the transplant procedures. Subjects will be monitored for clinical safety by history and standard exams and the follow-up questionnaire as well as followed closely by phone and in person.

Interventions

Reconstitution of normal flora by a stool transplant from a healthy individual to a C. difficile - infected recipient via colonoscopy or nasogastric tube

Sponsors

Massachusetts General Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
7 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Patients with recurrent or relapsing CDI defined as EITHER(13): * At least three episodes of mild-to-moderate CDI and failure of a 6-8 week taper with vancomycin with or without an alternative antibiotic (e.g. rifaximin, nitazoxanide). * At least two episodes of severe CDI resulting in hospitalization and associated with significant morbidity. * Willingness to accept risk of unrelated donor stool * Willingness to be randomized to NGT vs. colonoscopic delivery. * Able to consent for self, or parental assent/child assent as age appropriate.

Exclusion criteria

* Anatomic contraindication to NGT * Delayed gastric emptying syndrome * Known chronic aspiration * Contraindication to colonoscopy (ASA 4 or more) * High risk of bacterial translocation (Immunosuppression, cirrhosis etc) * Pregnant or breastfeeding women * Acute unrelated infection or comorbid illness exaccerbation

Design outcomes

Primary

MeasureTime frameDescription
Safetyup to 6 mo post FMTSafety is assessed by clinical symptoms, exam, signs (GI and systemic)

Secondary

MeasureTime frameDescription
Efficacy3 monthsEfficacy is defined as resolution of C. Difficile signs and symptoms off antibiotics for C. difficile

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 8, 2026